Back To Search Results

Percutaneous Lung Lesion Biopsy

Editor: Ronald Shapiro Updated: 2/14/2024 10:08:10 AM

Introduction

Percutaneous lung lesion biopsy (PLLB) is a procedure that involves passing a needle percutaneously under image guidance using a thoracic computed tomography scan. PLLB encompasses either transthoracic needle aspiration or transthoracic biopsy to diagnose lung cancer, the primary indication for deep thoracic tissue needle biopsies.[1] A separate article will discuss other transthoracic biopsies (such as mediastinal structures, pleura, or bones).[2] The PLLB approach's diagnostic yield is estimated at 93% (95% confidence interval, 90-96).[3]

PLLB has the highest complication rates among procedures performed by radiologists, with rates around 35%.[4] The technical difficulty for achieving tissue diagnosis without concurrent complication is broad. Some lesions and patients provide no difficulty, with a procedure time of fewer than 30 minutes. Others undergo failed tissue diagnosis even with procedure times extending to more than 90 minutes and attempts made on multiple occasions. This review on PLLB explores the relevant anatomy, indications, contraindications, preparation steps and techniques, and complications. 

Anatomy and Physiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Anatomy and Physiology

In the typical configuration, the lungs are divided into 5 lobes, with 3 on the right and 2 on the left. Surrounding the lobes are serous membranes known as pleural membranes. The inner lining of the thoracic wall is the parietal pleura, while the outer lining of the lungs is the visceral pleura. Between these membranes exists a potential space or cavity called the pleural space, typically containing minimal fluid. This fluid allows the visceral pleura to slide smoothly along the parietal pleura, maintaining surface tension and ensuring contact between the membranes. Maintaining this surface tension is crucial for keeping the lungs fully inflated.

The lungs receive a dual blood supply through bronchial and pulmonary arteries. The bronchial arteries are supplied by the aorta, with the most common configuration being 2 arteries to the left lung and 1 to the right. They bifurcate alongside the bronchi and bronchioles. Pulmonary arteries, on the other hand, are supplied by the right ventricle, with the typical configuration consisting of 1 pulmonary trunk, 1 primary artery per lung, and 1 secondary artery per pulmonary lobe.

In cases where pulmonary abnormalities are suspected, computed tomography scans are crucial for determining the most suitable technique for obtaining tissue. These techniques may involve bronchoscopic biopsy, surgical biopsy (often conducted using video-assisted thoracoscopic surgery), or percutaneous needle biopsy of the lung. Surgical biopsy is generally recommended for suspected interstitial lung disease or small peripheral lesions, particularly those at the lung bases, which may be unsuitable for a successful percutaneous needle biopsy. Conversely, bronchoscopy is preferred for lesions located centrally, whether endobronchial or peribronchial.[5] 

Indications

PLLB stands out as a valuable procedure, explicitly recommended for assessing indeterminate pulmonary nodules or masses--particularly in cases where chemotherapy or radiation may be more suitable than surgery. This method also proves advantageous for patients with a history of extrapulmonary malignancy. The growing significance of targeted therapy for treating lung cancer underscores the essential role of PLLB in obtaining tissue samples for molecular testing. Recent studies have demonstrated the effectiveness of fine-needle aspiration specimens in detecting epidermal growth factor receptor (EGFR) mutations in patients with lung cancer, enabling the precise identification of individuals who would benefit from EGFR tyrosine kinase inhibitors.[6] 

Moreover, PLLB extends its utility beyond lung cancer; PLLB proves instrumental in determining crucial factors such as estrogen and progesterone receptor status in breast cancer metastases. The procedure also plays a pivotal role in diagnosing focal pulmonary infections. Beyond its application in lung-related conditions, PLLB is commonly used for accessing lesions in the mediastinum, pleura, and chest wall.[5] The versatility and precision PLLB offers make it an indispensable tool in the diagnostic arsenal, contributing significantly to a comprehensive evaluation and targeted management of diverse pulmonary and extrapulmonary conditions.

The National Comprehensive Cancer Network, the American College of Chest Physicians, and the American Society of Clinical Oncology have created the following guidelines for diagnosing and treating lung cancer:

  • Patients with a strong clinical suspicion of stage 1 or 2 lung cancer, based on risk factors and radiologic appearance, do not require a biopsy before surgery. Performing a biopsy adds unnecessary time, costs, and procedural risks to treatment decisions.
  • A preoperative biopsy may be appropriate if a non-lung cancer diagnosis is strongly suspected and can be confirmed through core biopsy or fine needle aspiration.
  • A preoperative biopsy may be suitable if an intraoperative diagnosis appears difficult or highly risky. If a preoperative tissue diagnosis has not been obtained, an intraoperative diagnosis (eg, wedge resection, needle biopsy) is necessary before performing a lobectomy or pneumonectomy.
  • Invasive mediastinal imaging is recommended before surgical resection for most patients with clinical stage 1 or 2 lung cancer.
  • A patient's preferred diagnostic strategy depends on tumor size and location, mediastinal or distant disease presence, patient characteristics (including pulmonary pathology and comorbidities), and local expertise.
  • The initial diagnostic study should be the least invasive biopsy method with the highest yield.
  • Anatomic pulmonary resection is typically preferred for the majority of patients with nonsmall cell lung cancer.
  • Patients suspected of having metastatic disease should have confirmation from one of the metastatic sites, if feasible. However, if it is technically difficult or hazardous to biopsy a metastatic site, a biopsy of the primary lung lesion or mediastinal lymph nodes should be performed.
  • Patients with metastatic disease should have the histologic subtype established and adequate tissue available for molecular testing, including consideration for rebiopsy or plasma biopsy, to provide the best guidance for chemotherapy options.
  • Decisions regarding the optimal diagnostic steps for suspected stage 1, 2, or 3 lung cancer should be made by thoracic radiologists, interventional radiologists, interventional pulmonologists, and thoracic surgeons who specialize in thoracic oncology.
  • The preferred approach is a joint decision among a radiologist, a pulmonologist, and a medical or radiation oncologist.
  • In patients suspected of having small cell lung cancer based on radiographic and clinical findings, confirm the diagnosis pathologically using the least invasive method determined by the patient's presentation, such as sputum cytology, thoracentesis, fine needle aspiration, or transbronchial aspiration.
  • In patients suspected of having lung cancer with a solitary extrathoracic site suspicious of metastasis, obtaining tissue confirmation of the metastatic site through fine needle aspiration or biopsy is recommended.
  • In patients suspected of having lung cancer with lesions in multiple distant sites suspected of metastasis (but where a biopsy of a metastatic site would be technically difficult), diagnose the primary lung lesion by using the least invasive method.
  • For patients suspected of having lung cancer with a peripheral lung nodule, when tissue diagnosis is required due to diagnostic uncertainty or poor surgical candidacy, radial endobronchial ultrasound (EBUS) is recommended as an adjunct imaging modality. If radial EBUS is unlikely to achieve a diagnosis, electromagnetic navigation guidance is recommended if the equipment and expertise are available. If electromagnetic navigation is unavailable, then PLLB is recommended.
  • If initially obtained specimens are inadequate for histologic and molecular characterization, pursuing a second biopsy is acceptable due to the importance of accurate tumor characterization.
  • In the case of a small (<3 cm), solitary, peripheral lung lesion suspicious for lung cancer in a patient who appears to have early-stage disease and is a surgical candidate, the diagnostic dilemma often revolves around the necessity of obtaining a biopsy specimen to confirm the diagnosis before surgical resection. When the lesion is moderately to highly suspicious for lung cancer, surgical excision via thoracoscopy is the most definitive method for establishing a diagnosis and determining treatment. In nodules with an indeterminate likelihood of malignancy, sampling via PLLB or bronchoscopy with or without guidance technology (such as radial EBUS or electromagnetic navigation) may be considered.[7][8][9] 

The 2022 update of the National Comprehensive Cancer Network recommends molecular testing for mutations, such as BRAF and EGFR mutations, be performed using sufficient tissue samples from lung biopsies, particularly in patients with advanced or metastatic nonsmall cell lung cancer, to allow for targeted therapy or immunotherapy.[10]

Contraindications

General Contraindications

In certain cases, PLLB may not be feasible due to various relative contraindications. These contraindications include:

  • Uncooperative patients [11] 
  • Pulmonary hypertension (as determined by computed tomography or, more accurately, by right heart catheterization) 
  • Respiratory failure requiring positive-pressure ventilation (invasive or noninvasive ventilation) 
  • Severe hypoxic respiratory failure requiring oxygen supplementation 
  • Severe bullous emphysema
  • Extensive pleural disease
  • Contralateral pneumonectomy
  • End-stage pulmonary fibrosis
  • Severe impairment of diffusion capacity of the lungs for carbon monoxide (diffusing capacity of the lungs for carbon monoxide) <35% of predicted [12]
  • Recurrent cough (cough suppressants should be prescribed)
  • Severe interstitial lung disease [13] 
  • Uncorrectable coagulopathy [14]
  • Small lesions (<1 cm) located near the diaphragm
  • Central lesions adjacent to a large vessel
  • Coagulation abnormalities (platelet count less than 100,000/mL or activated partial thromboplastin time [aPTT] ratio or prothrombin time [PT] ratio greater than 1.4)[15]

Bleeding Risks

Before the procedure, a routine assessment of platelet count, PT, international normalized ratio (INR), and aPTT is performed. According to a recently published consensus guideline, administering clopidogrel should be suspended for 5 days before PLLB. Before the procedure, a single dose of low-molecular-weight heparin (enoxaparin) should be withheld. In cases where the INR exceeds 1.5, appropriate measures, such as administering fresh frozen plasma or vitamin K, should be taken to correct it. Platelet transfusion is recommended when platelet counts fall below 50,000/μL. Although the guideline does not explicitly advise withholding aspirin, if feasible, it is preferable to discontinue nonsteroidal anti-inflammatory drugs, including aspirin, 5 to 7 days before the procedure.[16] 

Standards of practice recommendations for the cessation of antiplatelet and anticoagulant medications for interventional radiology procedures are categorized based on hemorrhage risks from level 1 to level 3. PLLB is classified as a level 2 procedure. An INR of no more than 1.5 and a platelet count of at least 50,000 cells/μL are recommended for such procedures. The same guidelines offer specific criteria for the cessation of antiplatelet and anticoagulant medications for level 2 procedures.[17] 

The Johns Hopkins Surgical Risk Classification System categorizes PLLB as a category 2 procedure, primarily based on the potential need for blood replacement. This places PLLB on a scale of 1 to 4, where category 2 procedures involve a blood loss of up to 500 cc. In terms of risk, this is comparable to laparoscopic cholecystectomy and inguinal hernia repair. Both of these procedures are typically performed with an anesthesiologist or certified registered nurse anesthetist who can support hemodynamic correction, airway maintenance, and analgesia. A rapid large pneumothorax resulting from the biopsy can cause chest pain similar to that experienced during a heart attack or aortic dissection. Additionally, specific lesions, such as renal cell carcinoma or melanoma metastasis, may be anticipated to have high vascularity.[18]

The "Noncooperative" Patient

The reality of PLLB is that it is often performed on highly mobile targets without real-time imaging guidance. In this setting, a "noncooperative" patient (ie, a person who cannot lie still or breathe in a controlled fashion for the time needed to perform the biopsy) is a major contraindication to continuing the procedure.[19] Cooperation is usually a modifiable risk factor (discussed briefly below).

Contraindications to Sedation

While PLLB can be carried out under local anesthesia alone, conscious sedation is often employed to facilitate regular breathing and ensure patient immobility. Conscious sedation proves particularly beneficial for anxious individuals and elderly patients who experience arthritic discomfort and find it challenging to remain still during the procedure. Additionally, it is advantageous for biopsies of small lesions near the diaphragm in the lower lobes or lesions close to large central vessels. A combination of midazolam and fentanyl is routinely administered as part of the sedation protocol; however, this may be contraindicated in selected cases such as severe cardiopulmonary compromise, and preoperative assessment should be obtained. 

Equipment

Imaging Guidance

Imaging guidance is pivotal in PLLB, with computed tomography (CT) scan being the preferred technique. The decision on imaging guidance hinges on factors like lesion location, accessibility, and available expertise, all aimed at achieving accurate and safe needle placement, maximizing diagnostic yield, and minimizing potential risks to the patient. The preference for CT arises from its ability to visualize pulmonary abnormalities and their surrounding structures, ensuring precise needle placement and accurate targeting of the biopsy site.

While CT is the primary imaging modality, selecting guidance techniques may include ultrasound or fluoroscopy, depending on lesion characteristics and the healthcare team's expertise. Ultrasound guidance proves particularly valuable for peripheral lesions, providing real-time imaging and aiding needle placement without exposing the patient to ionizing radiation. On the other hand, fluoroscopy offers real-time visualization during needle manipulation and is often preferred for challenging lesions.

While CT remains the preferred imaging technique, there is a growing recognition of potential radiation exposure to the patient during CT-guided procedures.[20] As a response, CT fluoroscopy is gaining popularity for its real-time visualization capabilities during needle manipulation, particularly in challenging cases.[21] However, CT fluoroscopy has the drawback of potential radiation exposure to the operator. In situations involving peripheral lesions, ultrasound guidance emerges as a viable alternative. Ultrasound offers a safe option for needle placement and biopsy, providing effective visualization and guidance without radiation exposure.

Use of Intravenous Contrast

For lesion localization, an unenhanced CT alone is usually sufficient because the difference in density between the lung and nodule is a natural contrast. Occasionally, intravenous (IV) contrast agent administration may be required during the procedure to define vascular or mediastinal structures in the anticipated needle path.[22]

Patient and Room Setup

During PLLB procedures, ensure patients and the room are set up appropriately to address potential complications and emergencies. The following equipment and supplies should be readily available;

due to the possible need for immediate intervention or sedation administration during the procedure, the following is required for all patients:

  • A monitor capable of detecting blood pressure, cardiac rhythm, oxygen saturation, and carbon dioxide waveforms
  • A functioning IV line for administration of medications or fluids as needed

For the room setup:

  • Oxygen supply to ensure adequate oxygenation
  • Suction equipment for airway clearance, if necessary
  • Artificial airway and intubation equipment for managing airway emergencies
  • A bag valve mask for manual ventilation if needed
  • A resuscitation cart containing essential emergency medications and equipment

In cases where a pneumothorax may occur, the following additional equipment should be readily available:

  • Needle for Seldinger or trocar technique for introducing a chest tube
  • Chest tubes with or without a guidewire (size selection depends on the nature of the pneumothorax)
  • A valved tube or stopcock to facilitate chest tube insertion and drainage
  • A Heimlich valve for immediate treatment of tension pneumothorax
  • Wall suction for chest drainage
  • A chest drainage system for long-term management of pneumothorax, hydrothorax, or hemothorax
  • Connecting stopcocks and tubing for proper drainage and monitoring

Having this equipment readily accessible ensures prompt management of potential complications and emergencies during PLLB procedures.

Preparation

Before proceeding with PLLB, it is imperative to conduct a thorough patient assessment, including a comprehensive history, physical examination, and routine laboratory studies. Specifically, preoperative investigations are essential for individuals with risk factors associated with bleeding to evaluate coagulation indices. These investigations typically involve measuring the PT, aPTT, and platelet count. Furthermore, strict adherence to published guidelines on perioperative anticoagulation is crucial, necessitating the discontinuation of oral anticoagulants as recommended before undertaking PLLB. This adherence to established guidelines is paramount for ensuring patient safety and minimizing the risk of bleeding complications during the procedure.[15] 

The Society of Interventional Radiology guidelines provide recommendations for preparing for PLLB and other aspects of patient care in PLLB.[17][23] Pulmonary function assessment is an important preoperative investigation in all cases, and individuals with forced expiratory volume in 1 second <35% of predicted values should not undergo needle biopsy without further assessment by the multidisciplinary team.[15] Additionally, the multidisciplinary team should thoroughly review all recent and prior chest radiographs and CT scans as part of the preparation process.

Role of Patient Cooperation

Before undergoing a PLLB, thoroughly explain the biopsy procedure to the patient. Each patient possesses unique abilities to comprehend instructions and sustain specific positions. Those undergoing lung biopsies can face additional challenges such as debilitation, dyspnea, arthritis, hearing impairments, or sleep deprivation. Even for individuals with robust cognitive abilities, executing consistent breath holds can be demanding, requiring practice and coordination.

Although clinical trials have not definitively proven the superiority of a specific technique for consistent breath holds, it is crucial to emphasize the patient's role in contributing to a successful procedure. Encouraging patients to practice breath holding and extended periods of lying in the planned biopsy position can theoretically enhance the chances of a successful outcome.

Patient Positioning

The prone position is preferred whenever feasible due to its advantages over the supine and lateral decubitus positions. In the prone position, the posterior ribs experience less movement than the anterior ribs, the posterior intercostal spaces are wider, the patient cannot visualize the needle during the procedure, and they can recover in a more comfortable supine position. The prone position also minimizes chest wall motion during the procedure. In contrast, the supine position is associated with moderate chest wall motion, while the lateral decubitus position involves maximum chest wall motion. Results from a study by Ye et al. in 2015 showed that the association between patient position (lateral versus supine) and overall complication rates was statistically significant. Similarly, there was a significant association between patient position and the occurrence of hemorrhage.[24] 

Additionally, results from other studies have revealed that performing a PLLB in a prone position is associated with a lower risk of pneumothorax.[25] However, achieving a true prone position can be challenging unless specialized head support is available to facilitate comfortable breathing in this position. Alternatively, a prone oblique position allows the head to be turned to one side, with the arms positioned below the level of the shoulders. In certain cases, adjusting the scapula may be necessary for optimal access.

Ensuring patient comfort is paramount, and having their arms at their sides is generally preferred. All positions should aim to eliminate cervical or joint strain, pressure on "pressure points," and dyspnea, as these issues can lead to increased patient motion, prolonging the procedure duration and elevating associated risks.

Choice of Target Lesion in Cases of Multiple Lesions

Selecting a target for PLLB involves careful consideration beyond mere size. For instance, a pleura-based lesion measuring 1 cm can be safely accessed directly in the upper lung of a cooperative patient due to minimal respiratory movement in that region. However, the same-sized lesion in the lower lung presents challenges due to the heightened risk of respiratory misregistration during pleural puncture or subsequent sample collection.[26] 

Lung tumors exhibit significant mobility in various directions, regardless of their anatomical location. Therefore, conducting an individualized assessment of tumor mobility is crucial for accurate characterization.[27] For example, a large lesion in the craniocaudal dimension that either abuts the pleura or exhibits visual distinctiveness, particularly with adjacent airspace opacification extending to the pleura and confirmed hypermetabolism on prior positron emission tomography-CT, is an ideal target for percutaneous biopsy. The larger size enhances the likelihood of successfully hitting the target.

The craniocaudal dimension is more important than other lesion dimensions, particularly when using a machine lacking real-time CT fluoroscopy. This dimension dictates the lesion's visibility on the imaging monitor throughout the procedure. Opting for a peripheral thoracic location reduces the risk of encountering larger vessels and minimizes the potential for needle drift or inadvertent redirection during insertion. Avoiding aerated lung tissue upon entry decreases the likelihood of pneumothorax. Additionally, higher metabolic activity increases the probability of obtaining viable abnormal tissue.

When a large lesion in the craniocaudal dimension is unavailable as a target, an alternative ideal location neither abuts the pleura nor is central. This positioning allows room for needle redirection after a possible inadvertent initial pleural puncture without withdrawing the needle through the pleura but still avoiding proximity to larger central vessels.

The peridiaphragmatic region is considered the most mobile part of the lung, whereas the lung apex poses challenges regarding expansion following a pneumothorax. Lesions located in the upper region of the lower lobe are preferred over peridiaphragmatic and apical lesions for 2 primary reasons. First, this specific lung area experiences minimal movement during respiration. Second, the lower lobe can undergo compression due to gravity when the patient is supine after the procedure, aiding in preventing or reducing pleural air leaks.

If a patient has multiple lesions and a history of prior invasive thoracic procedures, it is advisable to select the side on which the previous surgery was performed for biopsy. This choice considers the potential increase in pleural adherence caused by scarring, which can help reduce the risk of pneumothorax. However, avoid puncturing the thoracotomy scar directly, as the presence of hard tissue can hinder needle manipulation.[28]

Emphasizing the significance of the morphological characteristics in the targeted area is paramount when considering a lung biopsy. Even seemingly benign conditions like round atelectasis or the more conventional non-round atelectasis can meet all the outlined criteria for an optimal "lesion," demonstrating heightened metabolic activity on positron emission tomography scans, similar to a region affected by parenchymal fibrosis. However, biopsying these abnormalities, whether accompanied by a mass or not, seldom results in clinically meaningful insights. True nodules or masses, on the other hand, are more likely to provide valuable material upon pathological examination. When contemplating a biopsy for pulmonary lesions, it is crucial to assess the following scenarios.

  • Small, immediately subpleural lesions pose challenges in timing needle entry to puncture them on the first attempt successfully. Also, maintaining the introducer needle within the lesion while obtaining multiple samples becomes difficult, increasing the risk of pneumothorax.
  • Small lesions near the heart are generally not suitable for biopsy. Cardiac motion can make it challenging to target the lesion accurately, increasing the risk of missing the intended area. Moreover, attempting a biopsy in such cases puts the patient at a high risk of pericardial or myocardial puncture, potentially leading to tamponade and fatal outcomes.
  • Nodules located along fissures, particularly in the superior portion of the right middle lobe just below the minor dome-shaped fissure, can present difficulties in targeting without inadvertently puncturing a second lobe. This unintended puncture leads to additional pleural punctures, even with an angled CT gantry.
  • Small lesions within the costophrenic sulci demonstrate significant movement, challenging accurate targeting. Inadvertent puncture of the diaphragm can occur, causing considerable pain, even without perforation of underlying structures such as the liver or spleen.
  • Ground glass or predominantly necrotic lesions often yield insufficient viable cellular material for diagnosis through needle sampling. The smaller the lesion, the less likely it is to provide diagnostic material. While nodules as small as 4 mm have yielded enough tissue for a confident diagnosis of nonsmall cell lung cancer, relying solely on the size of the lesion is not a reliable indicator of success.[29] 

In these scenarios, consider 2 possible alternative approaches: either plan to perform a thoracoscopic biopsy on the same day or the next day following the PLLB or directly proceed to thoracoscopic sampling. Each approach carries its inherent risks. Before initiating the procedure, it is essential to take the following steps:

  • Review the patient's allergies, medications, sedation plans, and relevant laboratory tests, such as platelet count and coagulation profile.
  • Thoroughly review the patient's imaging to confirm the size and precise location of the targeted sampling for diagnosis.
  • Conduct a preprocedural time-out, which includes confirming the precise location of the lesion.

These measures are crucial to ensure patient safety and optimize the accuracy and success of the biopsy procedure.

Technique or Treatment

The coaxial technique, which involves inserting a thinner sampling needle through a larger needle positioned at the edge of the lesion, offers several advantages compared to tandem punctures:

  • Multiple samples without repuncturing the pleura
    • Coaxial technique - several samples can be obtained without requiring additional pleural punctures until introducer needle develops significant friction due to coagulated blood
    • Improves procedure speed, reduces pain, and lowers the risk of puncture-related complications
  • Controlled depth and better maneuverability
    • Using a stiffer, larger needle in coaxial technique allows for better control of sampling depth and improved maneuverability during needle manipulation 
    • Facilitates accurate lesion targeting and increases the likelihood of obtaining sufficient tissue samples
  • Enhanced ability to manage complications
    • If pneumothorax occurs during the procedure, the introducer needle used in the coaxial technique often remains lodged in the lesion
    • Allows for the possibility of obtaining further samples and aids in managing pneumothorax
  • Versatile applications
    • A larger-bore needle selected for the coaxial technique can serve multiple purposes 
    • Can be used to obtain a biopsy gun specimen, insert a marker into the lesion for thoracoscopic resection or radiation therapy planning, or deliver a substance to seal the tract created during the procedure

Minimizing the number of puncture sites decreases the risk of pneumothorax. Coughing episodes can generate pressures exceeding 100 mm Hg, making non-patched or patched punctures susceptible to air entrance. In cases of visible tearing of the pleura, it allows air leakage at pressures as low as 1 to 2 mm Hg.[30]

In select high-risk scenarios, opting for a single puncture noncoaxial approach is more suitable and advantageous. Particularly for lesions with a history of hemorrhage or those suspected to be prone to bleeding, as well as lesions featuring a prominent internal air-bronchogram that elevates the risk of air embolism, the adoption of a single puncture noncoaxial approach becomes a prudent consideration. In these instances, the noncoaxial technique provides a more direct and targeted path to the lesion, minimizing the likelihood of complications linked to multiple punctures or prolonged needle manipulation. Not using a larger needle or a coaxial system facilitates a procedure characterized by precision, thereby reducing the potential for complications, especially in cases where the lesions are situated near critical structures or have a heightened risk of hemorrhage.

A meticulous evaluation of each case's unique circumstances and risks is imperative. This assessment should encompass factors such as the specific characteristics of the lesion, the patient's comorbidities, and the proficiency of the healthcare team. The decision to employ a single puncture noncoaxial approach should be tailored to each case, considering the potential benefits and risks of the procedure.

Breath Holding

During PLLB, it is important to maintain respiratory volume within the range of normal, quiet breathing. Puncturing the lung during a deep inspiration or expiration can result in tension on the needle when the lung returns to its normal state, increasing the likelihood of a pleural tear at the puncture site.

Precautions

Minimizing the time a needle crosses the pleural space is crucial to reduce the risk of complications during PLLB. Some precautions to consider to reduce the risk of complications:

  • Time management: Streamline the procedure and minimize delays. This includes reducing unnecessary interruptions, such as prolonged tissue sample review or inadequate imaging to detect potential complications. Ensuring personnel in the room have proper radiation safety equipment can also help maintain efficient workflow.
  • Cough suppression: Forceful coughing poses a risk of pleural tears and can lead to complications such as pneumothorax or air embolism if the needle is exposed in a vein. Procedures should be halted during episodes of coughing. Administering a cough suppressant medication or addressing the underlying cause of irritation can help minimize the risk. If coughing persists and compromises the procedure's safety, it may be necessary to terminate it.
  • Lung/pleural patch technique: A lung/pleural patch technique involves closing the pleural defect through the introducer needle after the procedure to prevent gas leakage from the puncture site. Various materials can be used, but the traditional approach involves using the patient's blood. However, a blood patch may not be necessary if the aerated lung has not been affected during the procedure. The effectiveness of a blood patch may be reduced if multiple punctures have been made or pneumothorax has already developed. While the technique has shown promise in lung biopsy models and actual patients, there is a lack of randomized trials comparing different blood patch techniques.[30]

Following blood patch placement and needle removal, some physicians opt to roll the patient into a position where the puncture site is downward. This initial repositioning should involve as many assistants as needed to ensure the patient remains passive, avoiding any straining or Valsalva maneuver. Executing the roll while the patient exhales can mitigate the likelihood of a forceful Valsalva maneuver. The needle removal and the repositioning should be swift, typically taking only a few seconds. The concept of puncture-site-down positioning was initially proposed by Zidulka in 1982.[31] 

In cases where a pneumothorax is known to be present, administering oxygen may facilitate the resorption of the existing pneumothorax. The underlying premise is that a higher partial pressure of oxygen accelerates the diffusive resorption of trapped pleural air, primarily composed of nitrogen (and carbon dioxide).

Follow-up Imaging

Immediately obtaining a chest radiograph following a biopsy is unnecessary unless symptoms or a declining oxygen saturation level indicate the possible presence of pneumothorax. Despite the technologist's best efforts, acquiring a radiograph at this juncture will likely involve some degree of patient straining or a Valsalva maneuver. Oxygen saturation levels provide sufficient clinical information to delay the initial image acquisition.

Conversely, if there is an initially subclinical issue, identify it before the patient is discharged. After spending several hours in the puncture-site-down position, the patient should be allowed to engage in activities resembling those they would perform at home before obtaining a chest x-ray. The most sensitive method for detecting intrapleural air via plain film radiography involves upright expiratory images in at least two views (eg, frontal and oblique). Without serial images, it is challenging to distinguish new or ongoing leakage from leakage that occurred immediately after the procedure and then ceased. Therefore, follow-up imaging should be conducted after the initial discovery of pneumothorax to assess the stability of the leak.

Patient Discharge

The decision to discharge a patient from the hospital, rather than admitting them for observation or treatment, depends on several factors, such as the patient's condition, home situation, and home location. A shorter observation period of 2 hours after a procedure can be safe for patients with no symptoms.[32] Similarly, if a patient has minor physical symptoms, signs, or evidence of pneumothorax on an x-ray, then only the following patients are candidates for discharge:

  • Can tolerate a larger pneumothorax
  • Has a responsible family member willing to stay the night with the patient 
  • Lives within range of transport to a medical facility or ambulance arrival within 10 to 15 minutes

Complications

PLLB is a procedure with a high complication rate. According to some standard practices, recommended benchmarks set the thresholds for pneumothorax and chest tube insertion rates at 45% and 20%, respectively. Surpassing these benchmarks prompts a comprehensive departmental review to formulate strategies to mitigate and decrease the incidence of these complications.[23] 

There is an increased risk when performing PLLB on patients who are obese, elderly, highly emphysematous, or are classified as category 4 patients (eg, they are unable to walk up a flight of stairs) by the American Society of Anesthesiologists. In such cases, it is necessary to prenotify consultant medical specialists (eg, an interventional pulmonologist or respiratory therapist) so they can be available on call from the outset. Following PLLB, deaths can occur due to hemorrhage (rate about 1%), air embolism (rate less than 1%), cardiac event, or tension pneumothorax.[33] 

Pneumothorax

Pneumothorax is a common complication of PLLB that occurs in approximately 25% of patients. However, the need for a chest tube is much less common, with rates ranging from 0% to 15%.[34] The most common risk factors associated with a higher incidence of biopsy-related pneumothorax include:

  • Long lesion depth (≥3 cm)
  • Small lesion size (≤4 cm)
  • Lesions without pleural contact
  • Emphysema 
  • Using a large needle gauge (≥18)
  • Crossing fissures or bulla
  • Multiple pleural punctures
  • Clinicians with limited experience [35]

Pain from pneumothorax is not a consistent phenomenon across patients. While some patients may experience pleuritic chest pain even with a small pneumothorax, others remain asymptomatic until a more substantial pneumothorax develops. The size of pneumothorax necessary to cause shortness of breath is highly variable and depends on the underlying condition of the lungs. 

If a pneumothorax occurs before completing the tissue retrieval, the subsequent step may involve reinflating the lung. If a patient experiences clinical deterioration and the lung loses its fixed position, it can be difficult to anticipate the target lesion's future position during subsequent needle advancements. Moreover, the lung may only be able to be balloted rather than punctured by needle thrusts.

If air leakage is detected during the procedure follow-up, it is crucial to adopt puncture site-down positioning for at least an additional hour. Once imaging confirms the leakage cessation, attempting upright positioning is advisable. Further steps involve discharge if leakage is not observed or repeating the cycle if leakage recurs. This cycle persists until 1 of the following conditions is met:

  • Patient can be safely discharged
  • Pleural drainage is warranted due to the following:
    • Persistent symptoms
    • A pneumothorax exceeding approximately 30%
    • A recurring pattern of leakage [30]

Visual-only estimates of percent pneumothorax tend to be unreliable. Calipers and an evidence-based formula are recommended for a more accurate assessment.[36] A pneumothorax extending along the lateral aspect of the chest typically necessitates evacuation.

In some instances, aspiration alone may obviate the need for chest tube placement, especially in patients with a substantial pneumothorax. Small gauge catheters, as fine as 4 French, can be employed via the Seldinger or trocar technique. Alternatively, a large gauge needle, such as a Hawkins-Akins needle (a non-sharp needle with a sharp trocar), can be used.

The most expeditious method for pneumothorax evacuation involves wall suction. Aspiration can also be deliberately employed to temporarily reexpand the lung, as seen in posterior-approach PLLB. This allows catheter placement under less urgent conditions in a separate, predetermined location for long-term use. Some studies propose using a saline tract sealant to reduce the need for chest drain insertion.[37] 

Although most pneumothoraces occur immediately after PLLB, some are delayed and manifest after discharge, with onset up to 2 weeks later, necessitating more extensive chest tube insertion.[35] 

Delayed pneumothorax is prevalent in patients with lesions in the upper lobe and those subjected to multiple punctures for small lesions. Individuals with biopsy-related pneumothorax should abstain from activities like scuba diving or air travel for at least 24 hours post-biopsy, with some earlier recommendations advocating for a waiting period of at least 72 hours.[38] 

Hemoptysis and Pulmonary Hemorrhage 

Pulmonary hemorrhage is a common complication of PLLB, with an estimated rate of up to 60%.[39] While hemoptysis is less frequent, occurring in approximately 10% of cases, it is particularly noteworthy in individuals receiving dual antiplatelets (excluding those on single-antiplatelet therapy).[40]

Hemoptysis is more likely to occur when puncturing a pulmonary cavity or an enlarged bronchus, both associated with bronchial artery hypertrophy. If there are unusually bloody specimens and ground-glass attenuation formation in the lung, it could indicate the possible development of clinically significant hemoptysis.

If these findings develop, then less aggressive biopsy manipulations are recommended. Administering oxygen is essential. Placing the patient with the biopsy side down can help prevent blood from seeping through the bronchi into the contralateral lung. If intubation becomes necessary, it should be executed using a dual-lumen tube. Should these measures prove ineffective, consultation for bronchoscopic tamponade of the lobar bronchus is recommended. Additional therapeutic options include bronchial and pulmonary artery embolization and surgical interventions.

Air Embolism

Air embolism is infrequent, affecting less than 1% of patients undergoing PLLB. This complication can arise from patient inhalation after trocar removal from a needle tip in a pulmonary vein or from the iatrogenic creation of a broncho-venous fistula. Manifestations may include unconsciousness, stroke-like symptoms, or seizures. Notably, only one-third of these cases result in substantial morbidity or mortality.[41] 

The patient should be positioned in the left lateral decubitus Trendelenburg position to prevent air from exiting the left atrium before dissolving. Oxygen should be administered to aid the absorption of nitrogen in the bubbles. Intubation and positive pressure ventilation may worsen the introduction of venous air in a bronchopleural fistula and should be avoided. While most hospitals do not have decompression/hyperbaric chambers, it would be an appropriate time to use them if one is available.

Clinical Significance

The Centers for Disease Control highlights lung cancer as the predominant cause of cancer-related mortality in the United States. Numerous societal guidelines advocate for making cancer treatment decisions based on both tumor histologic type and molecular markers. While exceptions may exist, the prevailing practice underscores the importance of obtaining a tissue diagnosis before initiating curative and palliative therapies.

However, recognizing the importance of viewing patients not solely as medical cases but as individuals, clinicians must appreciate that obtaining a tissue diagnosis through biopsy involves unique considerations for the person undergoing the biopsy. Challenges may include the patient being unable to be still for an adequate time to facilitate needle access, having difficulty consistently holding their breath, particularly in light of limitations in a hospital's CT fluoroscopy equipment, or the necessity for specialist consultation to optimize pre-biopsy and post-biopsy care. Such considerations prevent prolonged hospitalization or severe permanent injury from potential complications.

For these reasons and because most experienced interventional radiologists can reach a target of at least 5 mm diameter and less than 15 mm depth, the commonly asked question "Can the lesion be biopsied?" is generally inappropriate. The following 3 questions are more appropriate to decision-making for patient care:

  • "Has the lesion reached a size allowing a reasonable chance at a tissue yield, or is it more reasonable to wait to allow the lesion to grow in anticipation that a diagnosis will still likely be achieved before potential metastasis?"
  • "Assuming that biopsy is now appropriate, how should the clinician and patient work together to optimize the patient medically and psychologically to improve the likelihood of a safe and successful biopsy?"
  • "Anticipating that the biopsy attempt may not yield adequate tissue, what will plan B be?"

Enhancing Healthcare Team Outcomes

Performing PLLB requires a collaborative and multidisciplinary approach involving various healthcare professionals to ensure patient-centered care, optimal outcomes, safety, and effective team performance. Physicians are pivotal in diagnostic decision-making, procedure planning, and post-biopsy care coordination. Advanced practitioners contribute with their specialized skills in patient assessment and patient monitoring. They also often assist in procedural aspects. Nurses are integral in providing pre-procedural education, ensuring patient comfort, and post-biopsy monitoring. Pharmacists contribute by managing medication regimens, especially in cases where sedation or pain management is involved. Interprofessional communication is crucial, facilitating the exchange of critical information between team members to enhance procedural efficiency and patient safety. Coordinated efforts among these professionals are essential for a comprehensive approach to PLLB, addressing not only the technical aspects but also the patient's overall well-being and safety throughout the entire process. This collaborative approach ultimately improves patient outcomes, reduces complications, and enhances overall team performance in PLLB.

Nursing, Allied Health, and Interprofessional Team Interventions

After the procedure, the role of the nurse is crucial. As there is always a risk for hemothorax or pneumothorax, the nurse should evaluate the patient's pulmonary status in the recovery room. Furthermore, the nurse should ensure it is clear and functioning if there is a Heimlich valve or a drainage tube. Any drainage should be documented. The nurse should carefully review the chest x-ray report to determine if a pneumothorax exists.

Nursing, Allied Health, and Interprofessional Team Monitoring

Vitals signs, including pulse oximetry, should be monitored for several hours after the procedure. The chest should be auscultated, and output from any chest drain should be recorded. Patients discharged with a Heimlich valve should be educated on how to maintain it and when to return to the surgeon.

References


[1]

Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May:143(5 Suppl):e142S-e165S. doi: 10.1378/chest.12-2353. Epub     [PubMed PMID: 23649436]

Level 1 (high-level) evidence

[2]

Zwischenberger JB, Savage C, Alpard SK, Anderson CM, Marroquin S, Goodacre BW. Mediastinal transthoracic needle and core lymph node biopsy: should it replace mediastinoscopy? Chest. 2002 Apr:121(4):1165-70     [PubMed PMID: 11948048]

Level 2 (mid-level) evidence

[3]

Han Y, Kim HJ, Kong KA, Kim SJ, Lee SH, Ryu YJ, Lee JH, Kim Y, Shim SS, Chang JH. Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis. PloS one. 2018:13(1):e0191590. doi: 10.1371/journal.pone.0191590. Epub 2018 Jan 22     [PubMed PMID: 29357388]

Level 1 (high-level) evidence

[4]

Kim DY, Sun JS, Kim EY, Park KJ, You S. Diagnostic accuracy and safety of CT-guided percutaneous lung biopsy with a coaxial cutting needle for the diagnosis of lung cancer in patients with UIP pattern. Scientific reports. 2022 Sep 20:12(1):15682. doi: 10.1038/s41598-022-20030-z. Epub 2022 Sep 20     [PubMed PMID: 36127437]


[5]

Wu CC, Maher MM, Shepard JA. CT-guided percutaneous needle biopsy of the chest: preprocedural evaluation and technique. AJR. American journal of roentgenology. 2011 May:196(5):W511-4. doi: 10.2214/AJR.10.4657. Epub     [PubMed PMID: 21512038]


[6]

Smouse JH, Cibas ES, Jänne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009 Feb 25:117(1):67-72. doi: 10.1002/cncy.20011. Epub     [PubMed PMID: 19347832]


[7]

Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May:143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351. Epub     [PubMed PMID: 23649456]

Level 1 (high-level) evidence

[8]

Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Oct:16(10):1171-1182. doi: 10.6004/jnccn.2018.0079. Epub     [PubMed PMID: 30323087]


[9]

Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 20:36(9):911-919. doi: 10.1200/JCO.2017.76.7293. Epub 2018 Feb 5     [PubMed PMID: 29401004]

Level 2 (mid-level) evidence

[10]

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 May:20(5):497-530. doi: 10.6004/jnccn.2022.0025. Epub     [PubMed PMID: 35545176]

Level 1 (high-level) evidence

[11]

Takashima Y, Shinagawa N, Morinaga D, Nakamura J, Furuta M, Shoji T, Asahina H, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Tsujino I, Konno S. Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension. BMC pulmonary medicine. 2022 Nov 28:22(1):449. doi: 10.1186/s12890-022-02245-y. Epub 2022 Nov 28     [PubMed PMID: 36443763]


[12]

Ruud EA, Heck S, Stavem K, Søyseth V, Geitung JT, Ashraf H. Low diffusion capacity of the lung predicts pneumothorax and chest drainage after CT-guided lung biopsy. BMC research notes. 2022 Dec 1:15(1):353. doi: 10.1186/s13104-022-06234-6. Epub 2022 Dec 1     [PubMed PMID: 36457053]


[13]

Vaszar LT, Larsen BT, Swanson KL, Ryu JH, Tazelaar HD. Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease. Respirology (Carlton, Vic.). 2018 May:23(5):507-511. doi: 10.1111/resp.13223. Epub 2017 Nov 27     [PubMed PMID: 29178216]


[14]

de Margerie-Mellon C, de Bazelaire C, de Kerviler E. Image-guided biopsy in primary lung cancer: Why, when and how. Diagnostic and interventional imaging. 2016 Oct:97(10):965-972. doi: 10.1016/j.diii.2016.06.016. Epub 2016 Jul 29     [PubMed PMID: 27481575]


[15]

Manhire A, Charig M, Clelland C, Gleeson F, Miller R, Moss H, Pointon K, Richardson C, Sawicka E, BTS. Guidelines for radiologically guided lung biopsy. Thorax. 2003 Nov:58(11):920-36     [PubMed PMID: 14586042]

Level 1 (high-level) evidence

[16]

Jaffe TA, Raiff D, Ho LM, Kim CY. Management of Anticoagulant and Antiplatelet Medications in Adults Undergoing Percutaneous Interventions. AJR. American journal of roentgenology. 2015 Aug:205(2):421-8. doi: 10.2214/AJR.14.13342. Epub     [PubMed PMID: 26204296]


[17]

Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, Saad WE, Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement, Standards of Practice Committee of the Society of Interventional Radiology. Addendum of newer anticoagulants to the SIR consensus guideline. Journal of vascular and interventional radiology : JVIR. 2013 May:24(5):641-5. doi: 10.1016/j.jvir.2012.12.007. Epub     [PubMed PMID: 23622037]

Level 3 (low-level) evidence

[18]

Larocque N, Brook OR. Lung, Pleural, and Mediastinal Biopsies: From Preprocedural Assessment to Technique and Management of Complications. Seminars in interventional radiology. 2022 Jun:39(3):218-225. doi: 10.1055/s-0042-1751292. Epub 2022 Aug 31     [PubMed PMID: 36062222]


[19]

Lal H, Neyaz Z, Nath A, Borah S. CT-guided percutaneous biopsy of intrathoracic lesions. Korean journal of radiology. 2012 Mar-Apr:13(2):210-26. doi: 10.3348/kjr.2012.13.2.210. Epub 2012 Mar 7     [PubMed PMID: 22438689]


[20]

Tsalafoutas IA, Tsapaki V, Triantopoulou C, Gorantonaki A, Papailiou J. CT-guided interventional procedures without CT fluoroscopy assistance: patient effective dose and absorbed dose considerations. AJR. American journal of roentgenology. 2007 Jun:188(6):1479-84     [PubMed PMID: 17515365]

Level 2 (mid-level) evidence

[21]

Hiraki T, Mimura H, Gobara H, Iguchi T, Fujiwara H, Sakurai J, Matsui Y, Inoue D, Toyooka S, Sano Y, Kanazawa S. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 2009 Dec:136(6):1612-1617. doi: 10.1378/chest.09-0370. Epub 2009 May 8     [PubMed PMID: 19429718]

Level 2 (mid-level) evidence

[22]

Karam W, Samadi A, Acosta E, Hassan Z. Air Embolism as a Complication of Lung Biopsy and IV Contrast Administration. Kansas journal of medicine. 2023:16():71-73. doi: 10.17161/kjm.vol16.18682. Epub 2023 Mar 15     [PubMed PMID: 36970040]


[23]

Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC, Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous needle biopsy. Journal of vascular and interventional radiology : JVIR. 2010 Jul:21(7):969-75. doi: 10.1016/j.jvir.2010.01.011. Epub 2010 Mar 20     [PubMed PMID: 20304676]

Level 2 (mid-level) evidence

[24]

Ye J, Peng W, Chen D, Qiu Y, Lan N, Huang T, Ou Y, Li M, Huang W. Ultrasound-guided percutaneous biopsy of peripheral pulmonary lesions with 16-G core needles: study of factors that influence sample adequacy and safety. Clinical radiology. 2023 Jan:78(1):24-32. doi: 10.1016/j.crad.2022.08.130. Epub 2022 Sep 15     [PubMed PMID: 36116968]

Level 2 (mid-level) evidence

[25]

Nakamura M, Yoshizako T, Koyama S, Kitagaki H. Risk factors influencing chest tube placement among patients with pneumothorax because of CT-guided needle biopsy of the lung. Journal of medical imaging and radiation oncology. 2011 Oct:55(5):474-8. doi: 10.1111/j.1754-9485.2011.02283.x. Epub     [PubMed PMID: 22008165]


[26]

Park B, Park J, Shin KM, Lim JK, Hong J, Cha JG, Lee SM, Cho SH, Choi SH, Jeong JY, Do YW. Ultrasound-guided lung biopsy for small (≤2 cm) subpleural lung lesions: comparison of diagnostic yield and safety with larger lesions. Journal of thoracic disease. 2023 May 30:15(5):2485-2496. doi: 10.21037/jtd-22-1546. Epub 2023 Apr 7     [PubMed PMID: 37324103]


[27]

van Sörnsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MR, Graveland WJ, Senan S. Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. International journal of radiation oncology, biology, physics. 2003 Jun 1:56(2):348-54     [PubMed PMID: 12738308]


[28]

Fintelmann FJ, Troschel FM, Kuklinski MW, McDermott S, Petranovic M, Digumarthy SR, Sharma A, Troschel AS, Price MC, Hariri LP, Gilman MD, Shepard JO, Sequist LV, Piotrowska Z. Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. The oncologist. 2019 Dec:24(12):1570-1576. doi: 10.1634/theoncologist.2019-0158. Epub 2019 May 31     [PubMed PMID: 31152082]


[29]

Li H, Boiselle PM, Shepard JO, Trotman-Dickenson B, McLoud TC. Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules. AJR. American journal of roentgenology. 1996 Jul:167(1):105-9     [PubMed PMID: 8659351]

Level 2 (mid-level) evidence

[30]

Moore EH. Technical aspects of needle aspiration lung biopsy: a personal perspective. Radiology. 1998 Aug:208(2):303-18     [PubMed PMID: 9680552]

Level 3 (low-level) evidence

[31]

Zidulka A, Braidy TF, Rizzi MC, Shiner RJ. Position may stop pneumothorax progression in dogs. The American review of respiratory disease. 1982 Jul:126(1):51-3     [PubMed PMID: 7091910]

Level 3 (low-level) evidence

[32]

Ah-Lan KC, Nakhaei M, Camacho A, Appel E, Siewert B, Ahmed M, Brook OR. Safely Shortening the Observation Time After CT-Guided Lung Procedures. Journal of the American College of Radiology : JACR. 2021 Aug:18(8):1118-1127. doi: 10.1016/j.jacr.2021.03.015. Epub 2021 Apr 24     [PubMed PMID: 33905749]


[33]

Tomiyama N, Yasuhara Y, Nakajima Y, Adachi S, Arai Y, Kusumoto M, Eguchi K, Kuriyama K, Sakai F, Noguchi M, Murata K, Murayama S, Mochizuki T, Mori K, Yamada K. CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. European journal of radiology. 2006 Jul:59(1):60-4     [PubMed PMID: 16530369]

Level 2 (mid-level) evidence

[34]

Huo YR, Chan MV, Habib AR, Lui I, Ridley L. Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. The British journal of radiology. 2020 Apr 1:93(1108):20190866. doi: 10.1259/bjr.20190866. Epub 2020 Jan 3     [PubMed PMID: 31860329]

Level 1 (high-level) evidence

[35]

Bae K, Ha JY, Jeon KN. Pneumothorax after CT-guided transthoracic lung biopsy: A comparison between immediate and delayed occurrence. PloS one. 2020:15(8):e0238107. doi: 10.1371/journal.pone.0238107. Epub 2020 Aug 24     [PubMed PMID: 32834016]


[36]

Collins CD, Lopez A, Mathie A, Wood V, Jackson JE, Roddie ME. Quantification of pneumothorax size on chest radiographs using interpleural distances: regression analysis based on volume measurements from helical CT. AJR. American journal of roentgenology. 1995 Nov:165(5):1127-30     [PubMed PMID: 7572489]


[37]

Huo YR, Chan MV, Habib AR, Lui I, Ridley L. Post-Biopsy Manoeuvres to Reduce Pneumothorax Incidence in CT-Guided Transthoracic Lung Biopsies: A Systematic Review and Meta-analysis. Cardiovascular and interventional radiology. 2019 Aug:42(8):1062-1072. doi: 10.1007/s00270-019-02196-8. Epub 2019 Mar 12     [PubMed PMID: 30863965]

Level 1 (high-level) evidence

[38]

Tam A, Singh P, Ensor JE, Carter K, Kim ES, Hicks ME, Wallace MJ, Gupta S. Air travel after biopsy-related pneumothorax: is it safe to fly? Journal of vascular and interventional radiology : JVIR. 2011 May:22(5):595-602.e1. doi: 10.1016/j.jvir.2011.01.436. Epub     [PubMed PMID: 21514516]


[39]

Tai R, Dunne RM, Trotman-Dickenson B, Jacobson FL, Madan R, Kumamaru KK, Hunsaker AR. Frequency and Severity of Pulmonary Hemorrhage in Patients Undergoing Percutaneous CT-guided Transthoracic Lung Biopsy: Single-Institution Experience of 1175 Cases. Radiology. 2016 Apr:279(1):287-96. doi: 10.1148/radiol.2015150381. Epub 2015 Oct 19     [PubMed PMID: 26479161]

Level 3 (low-level) evidence

[40]

Song YS, Park CM, Park KW, Kim KG, Lee HJ, Shim MS, Goo JM. Does antiplatelet therapy increase the risk of hemoptysis during percutaneous transthoracic needle biopsy of a pulmonary lesion? AJR. American journal of roentgenology. 2013 May:200(5):1014-9. doi: 10.2214/AJR.12.8931. Epub     [PubMed PMID: 23617483]


[41]

Lee JH, Yoon SH, Hong H, Rho JY, Goo JM. Incidence, risk factors, and prognostic indicators of symptomatic air embolism after percutaneous transthoracic lung biopsy: a systematic review and pooled analysis. European radiology. 2021 Apr:31(4):2022-2033. doi: 10.1007/s00330-020-07372-w. Epub 2020 Oct 13     [PubMed PMID: 33051730]

Level 1 (high-level) evidence